BRPI0914139A2 - composições pediátricas para o tratamento de esclerose múltipla - Google Patents

composições pediátricas para o tratamento de esclerose múltipla

Info

Publication number
BRPI0914139A2
BRPI0914139A2 BRPI0914139A BRPI0914139A BRPI0914139A2 BR PI0914139 A2 BRPI0914139 A2 BR PI0914139A2 BR PI0914139 A BRPI0914139 A BR PI0914139A BR PI0914139 A BRPI0914139 A BR PI0914139A BR PI0914139 A2 BRPI0914139 A2 BR PI0914139A2
Authority
BR
Brazil
Prior art keywords
treatment
multiple sclerosis
pediatric compositions
pediatric
compositions
Prior art date
Application number
BRPI0914139A
Other languages
English (en)
Inventor
Goeril Karlsson
John Kovarik
Marie-Claude Bastien
Olivier David
Robert Schmouder
Thomas Bouillon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40974366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0914139(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0914139A2 publication Critical patent/BRPI0914139A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0914139A 2008-06-20 2009-06-19 composições pediátricas para o tratamento de esclerose múltipla BRPI0914139A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13262108P 2008-06-20 2008-06-20
PCT/US2009/047885 WO2009155475A1 (en) 2008-06-20 2009-06-19 Paediatric compositions for treating1 multiple sclerosis

Publications (1)

Publication Number Publication Date
BRPI0914139A2 true BRPI0914139A2 (pt) 2015-10-20

Family

ID=40974366

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914139A BRPI0914139A2 (pt) 2008-06-20 2009-06-19 composições pediátricas para o tratamento de esclerose múltipla

Country Status (16)

Country Link
US (11) US20110152380A1 (pt)
EP (3) EP3545953A1 (pt)
JP (7) JP2011525189A (pt)
KR (4) KR20110020928A (pt)
CN (2) CN104800196A (pt)
BR (1) BRPI0914139A2 (pt)
CA (1) CA2728514C (pt)
CL (1) CL2010001463A1 (pt)
IL (2) IL209725A (pt)
MA (1) MA32480B1 (pt)
MX (1) MX2010014223A (pt)
NZ (1) NZ589618A (pt)
RU (1) RU2562571C2 (pt)
SG (1) SG10201406263SA (pt)
WO (1) WO2009155475A1 (pt)
ZA (1) ZA201008478B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110020928A (ko) 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
CA2743232C (en) * 2008-11-11 2015-12-29 Novartis Ag Crystalline forms of fingolimod hcl
RS66784B9 (sr) * 2008-12-22 2025-08-29 Novartis Ag Režim doziranјa agonista s1p receptora
EP2482810A2 (en) 2009-09-29 2012-08-08 Novartis AG Dosage regimen of an s1p receptor modulator
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
EP3027174B1 (en) * 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5604229A (en) 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
US5912253A (en) 1993-12-17 1999-06-15 Novartis Ag Rapamycin derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
EP0833828B1 (en) 1995-06-09 2002-11-20 Novartis AG Rapamycin derivatives
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9903861D0 (en) 1999-02-20 1999-04-14 Zeneca Ltd Chemical compounds
EP1155010A1 (en) 1999-02-20 2001-11-21 AstraZeneca AB Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
AU2560000A (en) 1999-02-20 2000-09-04 Astrazeneca Ab Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin
WO2000051998A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
GB9907683D0 (en) 1999-04-06 1999-05-26 Synphar Lab Inc Substituted azetidin-2-ones as cysteine protease inhibitors
EP1043027A1 (en) * 1999-04-08 2000-10-11 Applied Research Systems ARS Holding N.V. Treatment of multiple sclerosis with a combination of Interferon and Growth hormone
GB9911417D0 (en) 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
GB9917909D0 (en) 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
CA2384974A1 (en) 1999-09-16 2001-03-22 Axys Pharmaceuticals, Inc. Compounds and pharmaceutical compositions as cathepsin s inhibitors
GB9930449D0 (en) 1999-12-23 2000-02-16 Promotion & Display Tech Ltd Handset
CO5280088A1 (es) 2000-04-18 2003-05-30 Smithkline Beecham Corp Inhibidores de proteasa
EP1309593B1 (en) 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
DK1309592T3 (da) 2000-08-14 2006-08-21 Ortho Mcneil Pharm Inc Substituerede pyrazoler
HK1052509B (en) 2000-08-14 2007-09-07 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazole
EP1326848A1 (en) 2000-10-19 2003-07-16 Naeja Pharmaceutical Inc. Dihydropyrimidine derivatives as cysteine protease inhibitors
JP2004523506A (ja) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド カテプシン阻害剤としての新規な化合物と組成物
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
US6900237B2 (en) 2001-09-14 2005-05-31 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
EP1436255A1 (en) 2001-09-14 2004-07-14 Aventis Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
AU2002340031A1 (en) 2001-10-02 2003-04-14 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
CA2463770A1 (en) 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
AU2002352663B2 (en) 2001-11-13 2007-06-21 Axys Pharmaceuticals, Inc. Cyanoalkylamino derivatives as protease inhibitors
YU34604A (sh) 2001-11-14 2006-08-17 Aventis Pharmaceuticals Inc. Oligopeptidi kao inhibitori katepsina s i kompozicije koje ih sadrže
EP1389480A1 (en) * 2002-08-14 2004-02-18 Mondobiotech Interferon SA Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation
KR20080103117A (ko) * 2002-09-24 2008-11-26 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
CA2521325C (en) 2003-04-08 2010-09-14 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
US20050009052A1 (en) * 2003-04-22 2005-01-13 Irm Llc, A Delaware Limited Liability Company Differential tag length analysis of cell proliferation
WO2005025553A2 (en) * 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
KR20090057399A (ko) 2006-09-26 2009-06-05 노파르티스 아게 Ｓ１ｐ 조정제를 포함하는 제약 조성물
KR20110020928A (ko) 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물

Also Published As

Publication number Publication date
US20210023027A1 (en) 2021-01-28
JP2018184424A (ja) 2018-11-22
CL2010001463A1 (es) 2011-05-06
JP2020063269A (ja) 2020-04-23
WO2009155475A1 (en) 2009-12-23
JP2023153786A (ja) 2023-10-18
KR20180017232A (ko) 2018-02-20
ZA201008478B (en) 2012-01-25
CA2728514C (en) 2020-08-11
US20130230489A1 (en) 2013-09-05
IL209725A0 (en) 2011-02-28
EP3011958A1 (en) 2016-04-27
US20190358178A1 (en) 2019-11-28
EP2303250A1 (en) 2011-04-06
SG10201406263SA (en) 2015-02-27
JP2017122106A (ja) 2017-07-13
AU2009259950A1 (en) 2009-12-23
IL248919B (en) 2018-12-31
US20170333368A1 (en) 2017-11-23
RU2011101771A (ru) 2012-07-27
MX2010014223A (es) 2011-01-21
CA2728514A1 (en) 2009-12-23
US20160022611A1 (en) 2016-01-28
US20180177747A1 (en) 2018-06-28
US20110152380A1 (en) 2011-06-23
JP2011525189A (ja) 2011-09-15
IL209725A (en) 2016-11-30
MA32480B1 (fr) 2011-07-03
RU2562571C2 (ru) 2015-09-10
US20170128389A1 (en) 2017-05-11
US20200197334A1 (en) 2020-06-25
JP2015107984A (ja) 2015-06-11
CN102076335A (zh) 2011-05-25
US20190117593A1 (en) 2019-04-25
KR20110020928A (ko) 2011-03-03
CN104800196A (zh) 2015-07-29
JP2021152016A (ja) 2021-09-30
KR20160131126A (ko) 2016-11-15
KR20170081755A (ko) 2017-07-12
EP3545953A1 (en) 2019-10-02
US20160206574A1 (en) 2016-07-21
IL248919A0 (en) 2017-01-31
NZ589618A (en) 2012-09-28

Similar Documents

Publication Publication Date Title
CY2023002I1 (el) Συνθεσεις και χρησεις για αντιμετωπιση πολλαπλης σκληρυνσης
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
HUE051206T2 (hu) Módszerek progresszív szklerózis multiplex kezelésére
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
BRPI0921237A2 (pt) métodos e composições para o tratamento de distúrbios associados ao complemento
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
LT2478907T (lt) Kompozicijos vėžiui gydyti
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
IL212651A (en) Preparations for the treatment of acute lymphoblastic leukemia in children
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
BRPI1014759A2 (pt) composto útil para o tratamento de doenças degenerativas e inflamatórias
BRPI0920009A2 (pt) composições concentradas para tratamento de superfícies rígidas
PL3443957T3 (pl) Związki i kompozycje stosowane w leczeniu nowotworów
BRPI0813670A2 (pt) Compostos para tratamento
SMT201400165B (it) Composizioni e metodi per il trattamento di sclerosi multipla
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI1013245A2 (pt) "composto para o tratamento de distúrbios metabólicos"
IL209360A (en) Medications containing pm00104 for the treatment of multiple myeloma
IL231907B (en) Compounds and compositions for treatment of transthyretin-associated amyloidosis
BRPI0914139A2 (pt) composições pediátricas para o tratamento de esclerose múltipla
BRPI0914454A2 (pt) "composição para o tratamento do tecido epitelial"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL